Targeting factor VIII expression to platelets for hemophilia A gene therapy does not induce an apparent thrombotic risk in mice

Christina K. Baumgartner(AbbVie (United States)), Robert R. Montgomery(Scripps Health), Hartmut Weiler(Versiti Blood Center of Wisconsin), Qizhen Shi(Children's Hospital of Wisconsin), Jeremy G. Mattson(Versiti Blood Center of Wisconsin)

Journal of Thrombosis and Haemostasis

August 6, 2016

10.1111/jth.13436

Cited by 21

Related Papers

Management of Postoperative Pain: A Clinical Practice Guideline From the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists' Committee on Regional Anesthesia, Executive Committee, and Administrative Council

|Journal of Pain|2016|3.1k

Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis

|Nature Medicine|2007|378

Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodies

|Journal of Clinical Investigation|2006|188

The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity

|Nature|2023|170

Effects of monoclonal antibodies against the platelet glycoprotein IIb/IIIa complex on thrombosis and hemostasis in the baboon.

|Journal of Clinical Investigation|1988|164